Floatz logo

Apnmab005

Tauopathies

APRINOIA Therapeutics, LLCPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

5 Active assets in the Tauopathies cohort.

Asset / SponsorPhaseRating
FLORTAUCIPIR
Columbia University
Phase 2BB
Donanemab
Eli Lilly and Company
Phase 3B
NA 831
Biomed Industries, Inc.
Phase 2B
Jaci-35.054
AC Immune SA
Phase 1/2CCC
Aci-35.030
AC Immune SA
Phase 1/2CCC

View all 14 →

Same molecule, other indications

Apnmab005 is also rated in:

Healthy VolunteersDormant
CC
Indicative ·
41 / 100
View asset →
Alzheimer diseaseDormant
C
Indicative ·
37 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →